Related Experiment Videos
[Clinical experience with cefotiam in pediatric infections (author's transl)]
Insights
Cefotiam antibiotic effectively treated pediatric infections, including respiratory and urinary tract infections, with an 85.7% response rate and no observed side effects. This new cephem antibiotic shows promise in pediatric infectious disease management.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antibiotic Therapy
Context:
- Pediatric infections pose significant health challenges.
- New antibiotics are crucial for combating resistant pathogens.
- Cephem antibiotics offer a valuable class of antimicrobial agents.
Purpose:
- To evaluate the efficacy and safety of Cefotiam in treating various pediatric infections.
- To assess clinical response rates and pathogen eradication.
- To identify any adverse effects associated with Cefotiam treatment.
Summary:
- Cefotiam was administered to 14 pediatric patients (15 days to 9 years) with infections like respiratory tract infections, urinary tract infections, meningitis, sepsis, and appendicitis.
- Daily doses ranged from 50-100 mg/kg intravenously, with treatment durations from 3 to 38 days.
- Clinical responses were good to excellent in 85.7% of cases, with pathogen eradication observed. No significant side effects were noted, though mild liver enzyme elevation occurred in one case.
Impact:
- Cefotiam demonstrates significant clinical efficacy and a favorable safety profile in pediatric patients.
- The study supports Cefotiam as a potential therapeutic option for a range of pediatric bacterial infections.
- Further investigation into potential superinfections and long-term effects is warranted.
Abstract:
Cefotiam, one of the new cephem antibiotics, was used in 14 cases with pediatric infections: (10 cases with respiratory tract infections, 2 with urinary tract infections, each 1 with purulent meningitis + sepsis and acute appendicitis). The patients were aged between 15 days and 9 years old. The drug was, a rule, given at a daily dose of 50 mg/kg to 100 mg/kg q.i.d. by bolus intravenous injection. The duration of treatment was between 3 and 38 days. The treatment produced the following clinical responses: Out of the 10 cases, good response in 7 with respiratory tract infections, fair in 1 and poor in the remaining 2. The responses in urinary tract infections were excellent in 1 and good in the other case. An apparently clear response was obtained in 1 case with purulent meningitis + sepsis due to K. pneumoniae. Also, an excellent response was seen in 1 case with acute appendicitis. The response rate including fair response was 85.7%. The suspected pathogens isolated from 5 cases (S. aureus: 1. strain, H. influenzae: 1, K. pneumoniae 2, E. coli: 1) were eliminated after CTM administration. Good clinical responses were also obtained in these cases. No side effect was observed. Mild elevation of GOT and GPT was noted during the treatment in 1 case. It is unclear, however, if CTM was associated with this side effect or not. P. aeruginosa, Serratia appeared after superinfection in 1 case.